SURF   $1.01  7.52% Market Closed

Surface Oncology Inc
Last Events:

2023-07-18 Trend pattern changed from канал to расширяющийся канал.

2023-07-18 Signal in Stochastic changed from bullish to bullish recovery. The stochastic indicator is in overbought territory and it heading north. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: main and signal line crossing.

2023-07-18 Signal in MACD changed from bullish to bullish recovery. Oscillator MACD is in the positive territory it's higher than the signal line and grows. These factors mean that positive mood prevails. Last signal: main and signal line crossing.

2023-07-18 Signal in RSI changed from bullish to bullish recovery. RSI indicator is in overbought territory and it heading north. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: entrance to the overbought zone.

2023-07-18 Signal in EMA100 changed from n/a to bullish reversal. 2023-06-16 the price crossed up the moving average line and formed a short-term upside trend.

2023-05-20 Signal in MACD changed from bearish weakening to bullish. Oscillator MACD is in the positive territory it's higher than the signal line and it crossed the zero line from the bottom. These factors mean that there is probably a growing trend. Last signal: up-crossing the middle level.

2023-05-19 Signal in EMA50 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-05-18 Signal in Stochastic changed from bearish to bullish. The stochastic indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: signal line crossed the middle level.


Current temperature: 3.61
ST: 0, Cor:

50-50 Year Forecast
Low with 50% probability: 0.81
Target: 2.38
High with 50% probability: 1.60
Analyst Recommendations:
Number of estimates 3
Target Price Mean 2.38
Mean unverified/preliminary 2.38 / 2.38
Target Price Low / High 1.00 / 5.00
Median / STD DEV 1.15 / 2.27
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell -
macd - Sell -
stoch - Sell -
ma20 Sell Sell Sell
ma50 Sell - -
ma100 Sell Sell -
Candlestick PatternJuly 6, 2023 Bearish Harami - consists of an unusually large white body followed by a small black body contained within. Large white body It is considered as a bearish pattern when preceded by an uptrend.
ISIN US86877M2098
ceo Dr. Robert W. Ross M.D.
Website https://www.surfaceoncology.com
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc.